Eli Lilly said sales of its blockbuster diabetes treatment, Trulicity, rose 20% from last year to $1.23 billion, but overall revenues missed analysts' forecasts. Eli Lilly & Co. (LLY) posted ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
Any drug that can make you skinny and rich at the same time must be a miracle. Ozempic and its competitor treatments are already handling the skinny side of the equation, and they're working ...
CAPE CANAVERAL, Fla. — Boeing Co. is now aiming for its first astronaut launch at the beginning of June, after spending the past few weeks struggling with more problems on the space capsule.
, opens new tab said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with ...
, opens new tab raised its profit forecast for the year on Tuesday, as its new CEO's turnaround plan helped to shield the department store chain from falling sales due to a cautious consumer.
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing sales ...
Revenue Growth: 26% increase in Q1. New Products Revenue: Nearly $1.8 billion growth compared to last year. Gross Margin: Increased from 78.4% in Q1 2023 to 82.5% in Q1 2024. Operating Income: Rose 63 ...